
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4B0DC8AF343E305B0DC002B16A7FC.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="taw">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Therapeutic Advances in Drug Safety">
<meta name="citation_title" content="Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review">
<meta name="citation_author" content="Giulia Matranga">
<meta name="citation_author_institution" content="Master in Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, and Real-World Evidence, University of Verona, Verona, Italy">
<meta name="citation_author" content="Anna Carollo">
<meta name="citation_author_institution" content="Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy">
<meta name="citation_author" content="Miriam Alaimo">
<meta name="citation_author_institution" content="Regional Pharmacovigilance Center, University of Messina, Messina, Italy">
<meta name="citation_author" content="Sofia Cutaia">
<meta name="citation_author_institution" content="Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy">
<meta name="citation_author" content="Sergio Rizzo">
<meta name="citation_author_institution" content="Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy">
<meta name="citation_author" content="Alessio Provenzani">
<meta name="citation_author_institution" content="Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Via E.Tricomi n. 5, Palermo 90127, Italy">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="16">
<meta name="citation_firstpage" content="20420986251347376">
<meta name="citation_doi" content="10.1177/20420986251347376">
<meta name="citation_pmid" content="40842734">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/pdf/10.1177_20420986251347376.pdf">
<meta name="description" content="Cholangiocarcinoma (CCA) is a cancer with a low survival rate. New drugs targeting molecular alterations, oncogenic mutations, and gene fusions are being tested as second-line treatments. This systematic review aims to summarize the results obtained ...">
<meta name="og:title" content="Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Cholangiocarcinoma (CCA) is a cancer with a low survival rate. New drugs targeting molecular alterations, oncogenic mutations, and gene fusions are being tested as second-line treatments. This systematic review aims to summarize the results obtained ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365427">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1177/20420986251347376"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/10.1177_20420986251347376.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365427%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365427/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365427/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-taw.png" alt="Therapeutic Advances in Drug Safety logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Therapeutic Advances in Drug Safety" title="Link to Therapeutic Advances in Drug Safety" shape="default" href="http://taw.sagepub.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Ther Adv Drug Saf</button></div>. 2025 Aug 19;16:20420986251347376. doi: <a href="https://doi.org/10.1177/20420986251347376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1177/20420986251347376</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Ther%20Adv%20Drug%20Saf%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ther%20Adv%20Drug%20Saf%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Ther%20Adv%20Drug%20Saf%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Ther%20Adv%20Drug%20Saf%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Matranga%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Giulia Matranga</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Giulia Matranga</span></h3>
<div class="p">
<sup>1</sup>Master in Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, and Real-World Evidence, University of Verona, Verona, Italy</div>
<div>Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Matranga%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giulia Matranga</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carollo%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Anna Carollo</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Anna Carollo</span></h3>
<div class="p">
<sup>2</sup>Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy</div>
<div>Conceptualization, Data curation, Supervision, Validation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carollo%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anna Carollo</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alaimo%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Miriam Alaimo</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Miriam Alaimo</span></h3>
<div class="p">
<sup>3</sup>Regional Pharmacovigilance Center, University of Messina, Messina, Italy</div>
<div>Investigation, Visualization, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alaimo%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Miriam Alaimo</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cutaia%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Sofia Cutaia</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Sofia Cutaia</span></h3>
<div class="p">
<sup>4</sup>Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy</div>
<div>Conceptualization, Validation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cutaia%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sofia Cutaia</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rizzo%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Sergio Rizzo</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Sergio Rizzo</span></h3>
<div class="p">
<sup>5</sup>Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy</div>
<div>Conceptualization, Project administration, Supervision, Validation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rizzo%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sergio Rizzo</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Provenzani%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Alessio Provenzani</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Alessio Provenzani</span></h3>
<div class="p">
<sup>6</sup>Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Via E.Tricomi n. 5, Palermo 90127, Italy</div>
<div>Conceptualization, Data curation, Methodology, Validation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Provenzani%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessio Provenzani</span></a>
</div>
</div>
<sup>6,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1-20420986251347376">
<sup>1</sup>Master in Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, and Real-World Evidence, University of Verona, Verona, Italy</div>
<div id="aff2-20420986251347376">
<sup>2</sup>Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy</div>
<div id="aff3-20420986251347376">
<sup>3</sup>Regional Pharmacovigilance Center, University of Messina, Messina, Italy</div>
<div id="aff4-20420986251347376">
<sup>4</sup>Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy</div>
<div id="aff5-20420986251347376">
<sup>5</sup>Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy</div>
<div id="aff6-20420986251347376">
<sup>6</sup>Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Via E.Tricomi n. 5, Palermo 90127, Italy</div>
<div class="author-notes p"><div class="fn" id="corresp1-20420986251347376">
<sup>✉</sup><p class="display-inline">Email: <span>aprovenzani@ismett.edu</span></p>
</div></div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Giulia Matranga</span></strong>: <span class="role">Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Anna Carollo</span></strong>: <span class="role">Conceptualization, Data curation, Supervision, Validation, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Miriam Alaimo</span></strong>: <span class="role">Investigation, Visualization, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Sofia Cutaia</span></strong>: <span class="role">Conceptualization, Validation, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Sergio Rizzo</span></strong>: <span class="role">Conceptualization, Project administration, Supervision, Validation, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Alessio Provenzani</span></strong>: <span class="role">Conceptualization, Data curation, Methodology, Validation, Writing – review &amp; editing</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Sep 13; Accepted 2025 May 16; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s), 2025</div>
<p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by-nc/4.0/</a>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<a href="https://us.sagepub.com/en-us/nam/open-access-at-sage" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://us.sagepub.com/en-us/nam/open-access-at-sage</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365427  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40842734/" class="usa-link">40842734</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="section1-20420986251347376"><h3 class="pmc_sec_title">Background:</h3>
<p>Cholangiocarcinoma (CCA) is a cancer with a low survival rate. New drugs targeting molecular alterations, oncogenic mutations, and gene fusions are being tested as second-line treatments.</p></section><section id="section2-20420986251347376"><h3 class="pmc_sec_title">Objectives:</h3>
<p>This systematic review aims to summarize the results obtained with three new targeted therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of CCA, evaluating their safety and tolerability profiles in patients, compared to current standard therapies.</p></section><section id="section3-20420986251347376"><h3 class="pmc_sec_title">Data sources and methods:</h3>
<p>A systematic literature search was performed with a cutoff date of July 24, 2023, in MEDLINE, Embase, and the Cochrane Library. The authors also conducted an advanced search in the ClinicalTrials.gov database, evaluated conference abstracts, article bibliographies, and drug monographs. Studies involving the treatment of patients with pemigatinib, futibatinib, and ivosidenib were considered. The selected studies had to report adverse events (AEs) that occurred during treatment with these therapies.</p></section><section id="section4-20420986251347376"><h3 class="pmc_sec_title">Results:</h3>
<p>The most common AEs observed with pemigatinib, futibatinib, and ivosidenib were alopecia, diarrhea, fatigue, and dysgeusia. In addition, hyperphosphatemia, hypophosphatemia, and ocular disorders were observed with fibroblast growth factor receptor (FGFR) inhibitors, while the isocitrate dehydrogenase 1 (IDH1) inhibitor was associated with dose-dependent prolongation of the corrected QT interval (QTc). These AEs were effectively managed through dose adjustments.</p></section><section id="section5-20420986251347376"><h3 class="pmc_sec_title">Conclusion:</h3>
<p>FGFR2 and IDH1 inhibitors have good tolerability in the population examined. All AEs were optimally managed with dose modulation. Future studies should focus on identifying the most effective dosages to further enhance treatment safety.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> adverse events, cancer, cholangiocarcinoma, clinical trials, FGFR, IDH1, rare disease, safety, systematic review</p></section></section><section class="abstract" id="abstract2"><h2>Plain language summary</h2>
<p>
Safety profiles of the new target therapies Pemigatinib, Futibatinib and Ivosidenib for the treatment of cholangiocarcinoma: a systematic review
</p>
<p><strong>Why was this study conducted?</strong> Cholangiocarcinoma is a rare and aggressive cancer with a low survival rate. New targeted therapies focusing on specific genetic alterations, such as mutations and gene fusions, are essential to improving patient outcomes and quality of life. This study aims to evaluate and compare the safety of three targeted treatments—pemigatinib, futibatinib, and ivosidenib—in patients with advanced cholangiocarcinoma.</p>
<p><strong>What did the researchers do?</strong> A team of doctors and pharmacists conducted a research of published studies to analyze safety data for patients treated with pemigatinib, futibatinib, or ivosidenib. They examined medical databases, as well as conference abstracts, article references, and drug monographs. Only studies reporting side effects (adverse events) during treatment were included.</p>
<p><strong>What did the researchers find?</strong> The most common side effects were mild and included hair loss, diarrhea, fatigue, and changes in taste. Pemigatinib and futibatinib were also linked to changes in blood phosphorus levels and eye problems. Ivosidenib was associated with dose-related prolongation of the QTc interval, a measure of heart rhythm. These side effects were effectively managed through dose adjustments.</p>
<p><strong>What do the results mean?</strong> Pemigatinib, futibatinib, and ivosidenib are generally well tolerated in patients with cholangiocarcinoma. Side effects can be managed by adjusting the dose. However, further research is needed to determine the optimal doses and enhance patient safety.</p></section><section id="section6-20420986251347376"><h2 class="pmc_sec_title">Introduction</h2>
<p>Cholangiocarcinoma (CCA) refers to a diverse group of malignant tumors arising from the intrahepatic and extrahepatic bile ducts within the liver.<sup>
<a href="#bibr1-20420986251347376" class="usa-link" aria-describedby="bibr1-20420986251347376">1</a>
</sup></p>
<p>CCA may be classified according to its anatomical location as intrahepatic (iCCA, those in the bile ducts that are proximal to second-order ducts) or extrahepatic (i.e., those occurring between the second-order ducts and the Ampulla of Vater). Extrahepatic CCA is further classified as either perihilar (pCCA) or ductal (dCCA). CCA subtypes are varied, showing differences in clinical presentation, associated risk factors, diagnostic pathways, and management strategies, along with distinct epidemiological, molecular, genetic, and clinical profiles.<sup>
<a href="#bibr2-20420986251347376" class="usa-link" aria-describedby="bibr2-20420986251347376">2</a>
</sup> Patients with CCA disease present heterogeneous characteristics, due to different genomic alterations that involve the tumor process. Alterations such as fusions, rearrangements, mutations, and overexpressions are oncogenic events that promote tumor progression.<sup>
<a href="#bibr3-20420986251347376" class="usa-link" aria-describedby="bibr3-20420986251347376">3</a>
</sup></p>
<p>CCA is a rare disease in Western countries, with an incidence of less than 1% of all human cancers and about 10%–15% of primary liver cancers.<sup>
<a href="#bibr4-20420986251347376" class="usa-link" aria-describedby="bibr4-20420986251347376">4</a>
</sup></p>
<p>A high mortality rate is reported for CCA due to its rapid progression, late diagnosis, and resistance mechanisms related to immunoregulatory abilities.<sup>
<a href="#bibr5-20420986251347376" class="usa-link" aria-describedby="bibr5-20420986251347376">5</a>
</sup></p>
<p>Although CCA is defined as a rare tumor pathology, recent epidemiological data suggest a global increase in recent decades, with increasing annual rates of incidence (0.3–6/100,000 inhabitants) and mortality (1–6/100,000 inhabitants).<sup>
<a href="#bibr6-20420986251347376" class="usa-link" aria-describedby="bibr6-20420986251347376">6</a>
</sup></p>
<p>Surgical resection with lymph node dissection at the hepato-duodenal ligament is the optimal treatment for CCA when achievable. For patients with unresectable or metastatic disease, systemic chemotherapy serves as the cornerstone of palliative therapy. A meta-analysis of Valle et al.<sup>
<a href="#bibr7-20420986251347376" class="usa-link" aria-describedby="bibr7-20420986251347376">7</a>
</sup> combining the results from two randomized trials (ABC-02, phase III and BT22, phase II) reported that the combination of cisplatin and gemcitabine chemotherapy reduces the risk of progression or death (defined by progression-free survival (PFS) event) by 36%; and risk of death by 35%, compared with gemcitabine monotherapy.</p>
<p>Clinical trials assessing the gemcitabine–oxaliplatin combination have shown a median overall survival (OS) of 8.3–12.4 months, with response rates ranging from 15% to 50%, and oxaliplatin presenting a more favorable toxicity profile compared to cisplatin. In addition, fluoropyrimidine-based chemotherapy has demonstrated effectiveness in advanced biliary tract cancers; however, a direct comparison between gemcitabine-based and fluoropyrimidine-based regimens remains unavailable.<sup>
<a href="#bibr7-20420986251347376" class="usa-link" aria-describedby="bibr7-20420986251347376">7</a>
</sup> Recently, further studies have led to the introduction and enhancement of first-line Cisplatin–Gemcitabine (CIS-GEM) therapy. The addition of durvalumab, the anti-Programmed Death-Ligand 1 (PD-L1) antibody based on the phase III study TOPAZ-1,<sup>
<a href="#bibr8-20420986251347376" class="usa-link" aria-describedby="bibr8-20420986251347376">8</a>
</sup> highlighted that the antibody, which acts as an immune checkpoint inhibitor (ICI), reported an OS median of 12.8 months.<sup>
<a href="#bibr9-20420986251347376" class="usa-link" aria-describedby="bibr9-20420986251347376">9</a>
</sup></p>
<p>Subsequently, the phase III ABC-06 clinical trial showed a benefit in treatment with FOLFOX (folinic acid, fluorouracil, and oxaliplatin) as a second line of therapy for patients diagnosed with advanced biliary tract cancer (72% CCA). Patients had already progressed on first-line cisplatin–gemcitabine treatment, with OS as the primary endpoint.<sup>
<a href="#bibr10-20420986251347376" class="usa-link" aria-describedby="bibr10-20420986251347376">10</a>
</sup></p>
<p>In recent years, the emergence of targeted therapies has demonstrated improvements in the survival of CCA patients with relevant genetic alterations. These innovative therapies have changed the landscape of possible treatment avenues.</p>
<p>ICIs have led to a targeted therapeutic approach that has improved the quality of life (QoL) of patients. The most prevalent genomic alterations involve mutations in isocitrate dehydrogenase 1 (IDH1) with a frequency rate of 15%–20%, fibroblast growth factor receptor 2 (FGFR2) fusions at 10%, Erb-b2 receptor tyrosine kinase 2 (ERBB2) for 5%–10%, and mutations of the BRAF gene involved in the MAPK/ERK signaling pathway for 3%.<sup>
<a href="#bibr11-20420986251347376" class="usa-link" aria-describedby="bibr11-20420986251347376">11</a>
</sup> Other mutations and rearrangements that have been found with a lower frequency rate involve the family of tyrosine kinase receptors NTRK (neurotrophic tyrosine receptor kinase) at 1%, the RET gene (Rearranged during Transfection) at 1%, and the KRAS gene (Kirsten Rat Sarcoma Virus) at 1%.<sup>
<a href="#bibr11-20420986251347376" class="usa-link" aria-describedby="bibr11-20420986251347376">11</a>
</sup></p>
<p>The most promising target molecules are ivosidenib in patients with mutations in IDH1, and pemigatinib, infigratinib, and futibatinib in patients with fusions or rearrangements of the FGFR2.<sup>
<a href="#bibr11-20420986251347376" class="usa-link" aria-describedby="bibr11-20420986251347376">11</a>
</sup> Currently, at the end of May 2024, the Food and Drug Administration (FDA) has announced the withdrawal of approval of infigratinib (Truseltiq) for previously treated, locally advanced unresectable or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.<sup>
<a href="#bibr12-20420986251347376" class="usa-link" aria-describedby="bibr12-20420986251347376">12</a>
</sup> In this systematic review of the literature, we analyze the safety profiles of pemigatinib, futibatinib, and ivosidenib. <a href="#fig1-20420986251347376" class="usa-link">Figure 1</a> lists the signaling pathways considered in this review.</p>
<figure class="fig xbox font-sm" id="fig1-20420986251347376"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365427_10.1177_20420986251347376-fig1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a83/12365427/6b83f02f06e4/10.1177_20420986251347376-fig1.jpg" loading="lazy" height="402" width="721" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1-20420986251347376/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanism of action of pemigatinib, futibatinib, and ivosidenib.</p></figcaption></figure><section id="section7-20420986251347376"><h3 class="pmc_sec_title">Study drugs</h3>
<p>In this systematic review, the drugs monitored and adverse reactions assessed were pemigatinib, futibatinib, and ivosidenib. Pemigatinib is an oral FGFR tyrosine kinase inhibitor that was recently granted accelerated approval by the FDA in April 2020 and obtained a conditional approval from the European Medicines Agency (EMA). The marketing authorization was issued on March 26, 2021, for the treatment of adults with previously treated drugs, unresectable locally advanced or metastatic CCA with FGFR2 fusion or rearrangement.<sup>
<a href="#bibr13-20420986251347376" class="usa-link" aria-describedby="bibr13-20420986251347376">13</a>
</sup></p>
<p>Pemigatinib is predominantly metabolized by CYP3A4 in vitro and is a CYP3A4 substrate; moderate and strong CYP3A4 inducers should be avoided during pemigatinib therapy.<sup>
<a href="#bibr14-20420986251347376" class="usa-link" aria-describedby="bibr14-20420986251347376">14</a>
</sup> The pharmacokinetics profile suggests that at steady state, pemigatinib concentrations increased proportionally over a 1–20 mg dose range and may be administered with or without food.<sup>
<a href="#bibr15-20420986251347376" class="usa-link" aria-describedby="bibr15-20420986251347376">15</a>
</sup> The median time to achieve peak pemigatinib plasma concentration was 1.13 h. The effect of severe renal impairment, renal dialysis in end-stage renal disease, or severe hepatic impairment on pemigatinib exposure remains unknown. Pemigatinib is excreted with 82.4% of the dose in feces (1.4% as unchanged) and 12.6% in urine (1% as unchanged).<sup>
<a href="#bibr16-20420986251347376" class="usa-link" aria-describedby="bibr16-20420986251347376">16</a>
</sup></p>
<p>Another important FGFR1–4 inhibitor is futibatinib, also known as TAS-120.<sup><a href="#bibr17-20420986251347376" class="usa-link" aria-describedby="bibr17-20420986251347376">17</a>,<a href="#bibr18-20420986251347376" class="usa-link" aria-describedby="bibr18-20420986251347376">18</a></sup> The treatment dose of futibatinib is one 20 mg oral dose per day, has a half-life of 2.9 h, and is 95% bound to plasma proteins. Its metabolism occurs mainly via cytochrome CYP3A, to a small extent via CYP2C9 and CYP2D6.<sup><a href="#bibr19-20420986251347376" class="usa-link" aria-describedby="bibr19-20420986251347376">19</a>,<a href="#bibr20-20420986251347376" class="usa-link" aria-describedby="bibr20-20420986251347376">20</a></sup> The compound is well absorbed and does not present dose accumulation in the body after daily administration. Furthermore, the results demonstrate that no dose adjustment is necessary for mild, moderate, or severe hepatic impairment in patients treated with futibatinib.<sup>
<a href="#bibr21-20420986251347376" class="usa-link" aria-describedby="bibr21-20420986251347376">21</a>
</sup> The EMA report showed that the mean elimination half-life (t1/2) of futibatinib was 2.94 (CV of 26.5%) hours, and its excretion after a single oral dose of 20 mg occurs for approximately 64% in feces and 6% in urine. In September 2022, the FDA granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced, or metastatic iCCA with FGFR2 fusions or other rearrangements and obtained conditional approval from the EMA, and the marketing authorization was issued on July 4, 2023.</p>
<p>Patients with CCA may present numerous genomic alterations these mutations also including those of the IDH1. Ivosidenib (AG-120) is an oral, potent, targeted IDH1 variant inhibitor approved for the treatment of adult patients with previously treated locally advanced or metastatic CCA with an IDH1 mutation.<sup><a href="#bibr22-20420986251347376" class="usa-link" aria-describedby="bibr22-20420986251347376">22</a>,<a href="#bibr23-20420986251347376" class="usa-link" aria-describedby="bibr23-20420986251347376">23</a></sup> In the ClarIDHy treatment trial, patients received a 500 mg dose of ivosidenib per day, equivalent to two tablets, for 28 consecutive days. The mean apparent clearance of ivosidenib at steady state is 6.1 L/h (31%) with a mean terminal half-life of 129 h (102%). Metabolism occurs through CYP3A4, of which it is a strong inducer, and to a lesser extent through N-dealkylation and hydrolytic pathways. Its elimination occurs by 77% via feces (67% unchanged) and 17% in urine (10% unchanged).<sup>
<a href="#bibr22-20420986251347376" class="usa-link" aria-describedby="bibr22-20420986251347376">22</a>
</sup></p>
<p>On August 25, 2021, the FDA approved ivosidenib for the treatment of CCA; ivosidenib is the first IDH1 inhibitor recommended for approval in Europe, and the marketing authorization was issued on May 4, 2023.</p></section><section id="section8-20420986251347376"><h3 class="pmc_sec_title">Aims and objectives</h3>
<p>The greatest challenge in the research and development of drugs that can specifically target mutations or alterations/rearrangements in CCA may lie in managing adverse effects and potential drug tolerance. A further understanding of the safety profiles of these new targeted therapies could help evaluate their toxicity profiles and facilitate treatment choice based on the scientific evidence produced. This systematic review explores the safety profiles of pemigatinib, futibatinib, and ivosidenib across phase II and III clinical trials. The topic chosen in this systematic review was recently discovered, and the drugs mentioned are approved by the FDA and EMA drug regulatory agencies in recent years. These premises determine a limitation of the number of articles available in the literature that can be included in the review. The research was conducted by reviewing the available gray literature, but no records met the inclusion criteria. This opens the search to integrations of safety data that can be extrapolated from the trials.</p></section></section><section id="section9-20420986251347376"><h2 class="pmc_sec_title">Methods</h2>
<section id="section10-20420986251347376"><h3 class="pmc_sec_title">Data selection</h3>
<p>The study was conducted from May 2023 to July 24, 2023, using the Medline, Cochrane Library, and Embase databases. A screening of all the data available in the literature was performed, given the innovativeness of pemigatinib, futibatinib, and ivosidenib. We conducted the research following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.<sup>
<a href="#bibr24-20420986251347376" class="usa-link" aria-describedby="bibr24-20420986251347376">24</a>
</sup> The data collected were selected based on the PICOS framework (participants, interventions, comparisons, outcomes, and study design), as shown in <a href="#table1-20420986251347376" class="usa-link">Table 1</a>. The development of the desired PICO for the research of this review is available in the <a href="https://journals.sagepub.com/doi/suppl/10.1177/20420986251347376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Material</a>. The database search sought to identify cases of suspected adverse events (AEs) associated with the use of pemigatinib, futibatinib, and ivosidenib that emerged during treatment.</p>
<section class="tw xbox font-sm" id="table1-20420986251347376"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Formulation of the participants, interventions, comparisons, and outcomes question for the systematic review.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
</colgroup>
<tbody>
<tr>
<td rowspan="1" colspan="1">P (patients, population, or problem)</td>
<td rowspan="1" colspan="1">Patients suffering from cholangiocarcinoma, with unresectable stage III/IV cancer, previously treated with first-line therapy and who have received treatment with pemigatinib, futibatinib, or ivosidenib.</td>
</tr>
<tr>
<td rowspan="1" colspan="1">I (intervention, factor prognostic, or factor of risk)</td>
<td rowspan="1" colspan="1">Treatment with biologics pemigatinib or futibatinib (if the patient has FGFR2 fusion) and ivosidenib (if the patient has IDH1 mutation).</td>
</tr>
<tr>
<td rowspan="1" colspan="1">C (comparison)</td>
<td rowspan="1" colspan="1">Safety profile of pemigatinib, futibatinib, and ivosidenib compared with standard first-line therapy or placebo.</td>
</tr>
<tr>
<td rowspan="1" colspan="1">O (outcomes of interest)</td>
<td rowspan="1" colspan="1">Are pemigatinib, futibatinib, or ivosidenib (targeted therapies) associated with a lower risk of adverse events?</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table1-20420986251347376/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn1-20420986251347376"><p>FGFR2, fibroblast growth factor receptor 2; IDH1, isocitrate dehydrogenase 1.</p></div></div></section><p>We also performed searches using Medical Subject Headings (MeSH), such as “cholangiocarcinoma,” “biliary tract cancer,” “FGFR inhibitors,” “IDH1 inhibitors,” “pemigatinib,” “futibatinib,” “ivosidenib,” “drug-related side effects and adverse reactions,” and “adverse reactions.”</p>
<p>An advanced search of the ClinicalTrials.gov database was also conducted by selecting the following filters: Condition or disease: “cholangiocarcinoma.” Other terms: “pemigatinib,” “futibatinib,” “ivosidenib.” Eligibility criteria: “adult,” “over 18,” “elderly adult.” Type of study: “interventional studies” (clinical studies). Study results: “studies with results.” Status: “finished” and “completed.”</p>
<p>There were no limitations on language or geographic location; Rayyan software was used to import and manage all the research results. The process of collection, selecting, and confirming the records involved a triple check by three reviewers based on the results obtained. It was deemed appropriate not to perform a meta-analysis, as the number of studies found was too small for statistical analysis, and the trials were of different types. Therefore, the aim of this paper is a critical analysis of drug safety.</p></section><section id="section11-20420986251347376"><h3 class="pmc_sec_title">Inclusion and exclusion criteria</h3>
<p>In this systematic review, common eligibility criteria were defined for pemigatinib, futibatinib, and ivosidenib. Study characteristics such as stage three or four of the tumor, age, and previous chemotherapy treatments were examined. The reviewers, given the innovative nature of drugs, did not limit the search to the English language alone, and the selection process involved several phases. Detailed inclusion criteria are presented in <a href="#table2-20420986251347376" class="usa-link">Table 2</a>.</p>
<section class="tw xbox font-sm" id="table2-20420986251347376"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Inclusion criteria.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Drugs</th>
<th align="left" rowspan="1" colspan="1">Criteria</th>
</tr></thead>
<tbody><tr>
<td rowspan="1" colspan="1">Pemigatinib, futibatinib, and ivosidenib</td>
<td rowspan="1" colspan="1">Patients over 18 years of age, regardless of gender.<br>Cytological diagnosis of advanced stage III/IV cholangiocarcinoma or metastatic cholangiocarcinoma with documentation of disease progression.<br>Diagnosis of inoperable tumor in patients who have previously received systemic therapy.<br>Patients included in the systematic review must have received treatment with one of the following drugs: pemigatinib, futibatinib, or ivosidenib.<br>The selected studies must show the adverse events associated with the treatment of the therapy.</td>
</tr></tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table2-20420986251347376/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="section12-20420986251347376"><h3 class="pmc_sec_title">Literature selection and submission of materials</h3>
<p>A comprehensive systematic review of the literature was carried out according to the inclusion criteria.</p>
<p>The initial search was conducted by two authors, and to ensure the accuracy and reliability of the search strategy, a third author independently re-ran the database search and verified the number of citations identified. The specific search strategy, as elaborated for each mentioned database, is available as <a href="https://journals.sagepub.com/doi/suppl/10.1177/20420986251347376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Material</a>.</p>
<p>To identify additional articles relevant to understanding the drugs’ safety profiles, citation monitoring was performed by examining the references of the identified studies, monitoring citations, and appropriately evaluating related articles. Finally, a follow-up search was conducted on gray literature sources to best complete the update phases of the study.</p>
<p>In the first screening phase, after collecting all the records, duplicates were eliminated with the help of Rayyan software and reviewers.</p>
<p>A second-level screening was based on reading the titles and abstracts; all references that were ineligible and not compliant with the scope of this systematic review were eliminated following the eligibility criteria defined upstream and set on the PICOS model defined previously. Finally, in the third screening phase, the full text of potentially eligible studies was reviewed to identify which were eligible and which were to be excluded as they did not meet the characteristics. The title and abstract screening process was carried out by three researchers, and any discrepancies were discussed and resolved, allowing for consistency of records according to the inclusion criteria.</p></section></section><section id="section13-20420986251347376"><h2 class="pmc_sec_title">Risk of bias assessment and quality assessment</h2>
<p>In this systematic review, the potential risk of bias was assessed to ensure the highest possible methodological quality of the included studies. The evaluation was performed independently by two reviewers, with any discrepancies resolved through discussion and, when necessary, with the involvement of a third reviewer to reach consensus.</p>
<p>For randomized controlled trials (RCTs), the Cochrane Risk of Bias tool, version 2 (RoB 2) was employed.<sup>
<a href="#bibr25-20420986251347376" class="usa-link" aria-describedby="bibr25-20420986251347376">25</a>
</sup> This tool was applied exclusively for one study conducted, as it was the only RCT included in the review.</p>
<p>Non-randomized studies evaluating the effects of interventions play a pivotal role in assessing the efficacy and safety of healthcare interventions, particularly in the early phases of oncological clinical research (i.e., phase I and II studies). However, the methodological tools currently available for risk of bias assessment have been primarily developed for comparative study designs and are therefore unsuitable or suboptimal for use in single-arm studies. At present, no universally accepted and validated instrument exists for assessing the risk of bias in non-comparative studies.</p>
<p>To address this methodological gap, the ROBINS-I (Risk Of Bias In Non-randomized Studies—of Interventions)<sup>
<a href="#bibr26-20420986251347376" class="usa-link" aria-describedby="bibr26-20420986251347376">26</a>
</sup> tool was introduced. This tool allows for a structured and systematic evaluation of risk of bias even in single-arm cohort studies, thus representing a significant methodological advancement in the context of systematic reviews that include evidence from non-randomized observational research. In the present review, this tool was applied to assess three non-randomized studies. The complete risk of bias assessment is available as <a href="https://journals.sagepub.com/doi/suppl/10.1177/20420986251347376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Material (Figures S1 and S2)</a>.</p></section><section id="section14-20420986251347376"><h2 class="pmc_sec_title">Results</h2>
<p>In the literature search process, 729 studies potentially relevant to this systematic review were initially identified. In the next phase, following an initial screening, a total of 174 duplicates were removed. In the subsequent screening, starting from 555 records, a total of 546 records were excluded after title and abstract selection. These studies did not meet the eligibility criteria; furthermore, many of them were only descriptive of the molecules under examination and did not provide sufficient original data. In this systematic review, only nine studies followed a process of reading the full text to evaluate the eligibility criteria. No further studies were identified by the literature search. After reading the full text, five studies were excluded. Studies were excluded as they did not meet the inclusion criteria, such as explaining safety data. Finally, four studies were included in this systematic review. The flowchart of the literature retrieval and screening process, along PRISMA lines, is presented in the flowchart in <a href="#fig2-20420986251347376" class="usa-link">Figure 2</a>. <a href="#table3-20420986251347376" class="usa-link">Table 3</a> presents a summary of the four included studies, which include one RCT study and three multicenter phase II observational studies.</p>
<figure class="fig xbox font-sm" id="fig2-20420986251347376"><h3 class="obj_head">Figure 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a83/12365427/1d9824f9774d/10.1177_20420986251347376-fig2.jpg" loading="lazy" height="967" width="798" alt="Figure 2."></p>
<div class="p text-right font-secondary"><a href="figure/fig2-20420986251347376/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flowchart of the screening process for included studies.</p></figcaption></figure><section class="tw xbox font-sm" id="table3-20420986251347376"><h3 class="obj_head">Table 3.</h3>
<div class="caption p"><p>Summary of the four included studies.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Drugs</th>
<th align="left" rowspan="1" colspan="1">Authors, year, country</th>
<th align="left" rowspan="1" colspan="1">Study design</th>
<th align="left" rowspan="1" colspan="1">Characteristics of the enrolled population</th>
<th align="left" rowspan="1" colspan="1">Intervention/comparison (<em>n</em> randomized)</th>
<th align="left" rowspan="1" colspan="1">Outcomes studied</th>
<th align="left" rowspan="1" colspan="1">Follow-up</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Pemigatinib</td>
<td rowspan="1" colspan="1">Abou-Alfa et al. <em>Lancet Oncol</em>. 2020.<br>USA, Europe, the Middle East, and Asia</td>
<td rowspan="1" colspan="1">Multicenter, open-label, single-arm, multicohort, phase II study (FIGHT-202).<br>Three cohorts:<br>(A) patients with FGFR2 fusions or rearrangements;<br>(B) patients with other FGF/FGFR alterations;<br>(C) patients with no FGF/FGFR alterations.</td>
<td rowspan="1" colspan="1">• 146 patients enrolled.<br>• The average age of all patients is 59 years.<br>• In the study, 58% of patients are female.<br>• 61% of patients are from North America.<br>• 86% of patients had metastases, and 61% had already received at least one systemic therapy.<br>• 89% of patients had intrahepatic cholangiocarcinoma.</td>
<td rowspan="1" colspan="1">All patients self-administered oral pemigatinib at a starting dose of 13.5 mg once daily (21-day cycle).<br>The study was not designed to make statistical comparisons between cohorts.</td>
<td rowspan="1" colspan="1">Primary outcome: patients (with FGFR2 fusions or rearrangements) who achieved an objective response.<br>Secondary outcomes: patients (with other FGF/FGFR alterations, patients with FGF/FGFR alterations, and in patients with no FGF/FGFR alterations) with an objective response, and duration of response, the proportion of patients with disease control, PFS, OS, safety in all cohorts, and population pharmacokinetics.</td>
<td rowspan="1" colspan="1">Overall median follow-up was 17.8 months (IQR 11.6–21.3).<br>Median follow-up in patients:<br>FGFR2 fusion or rearrangement is 15.4 months (IQR 9.3–19.0);<br>Another FGF/FGFR alteration is 19·9 months (19.2–21.1);<br>No FGF/FGFR alteration is 24.2 months (23.7–24.7).</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Pemigatinib</td>
<td rowspan="1" colspan="1">Shi et al. <em>Cancer Medicine</em>. 2022.<br>14 hospitals in China.</td>
<td rowspan="1" colspan="1">Multicenter, single-arm, phase II study.<br>The study included a single court with patients who had an FGFR2 alteration.</td>
<td rowspan="1" colspan="1">• 31 patients were enrolled who received at least one dose of pemigatinib.<br>• 56 is the average age of the patients enrolled.<br>• 67% of patients are female.<br>• All patients, except 1, had intrahepatic<br>cholangiocarcinoma.<br>• 51.6% received at least one systemic therapy.</td>
<td rowspan="1" colspan="1">Patients received 13.5 mg oral pemigatinib once daily (3-week cycle; 2 weeks on, 1 week off).<br>There is no comparison.</td>
<td rowspan="1" colspan="1">Primary endpoint: ORR (complete or partial response) according to RECIST v1.1.<br>Secondary end-points: investigator assessed ORR (per RECIST v1.1), PFS, DOR, DCR, OS, time to response, safety, and tolerability.</td>
<td rowspan="1" colspan="1">The median duration of follow-up was 5.1 months (range, 1.5–9.3) in the efficacy evaluable population/per-protocol set.</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Futibatinib</td>
<td rowspan="1" colspan="1">Goyal et al. <em>The New England Journal of Medicine</em> 2023<br>North America, Europe, Asia Pacific, Japan.</td>
<td rowspan="1" colspan="1">Multinational, open-label, single-group, phase II study.<br>The study included patients with FGFR2 fusion–positive or FGFR2 rearrangement—positive intrahepatic cholangiocarcinoma.</td>
<td rowspan="1" colspan="1">• 103 patients were selected for the study.<br>• The average age is 58 years.<br>• Females represent 56% of total patients.<br>• 78% of patients have FGFR2 fusion.<br>• 47% of patients received at least one systemic treatment.</td>
<td rowspan="1" colspan="1">The patients received oral futibatinib at a dose of 20 mg once daily in a continuous regimen.<br>There is no comparison.</td>
<td rowspan="1" colspan="1">Primary endpoint: objective response, as assessed by independent central review.<br>Secondary endpoint: response duration, progression-free and OS, safety, and patient-reported outcomes.</td>
<td rowspan="1" colspan="1">The median follow-up was 17.1 months (range, 10.1–29.6) in patients with FGFR2 fusions or rearrangements.</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Ivosidenib</td>
<td rowspan="1" colspan="1">Zhu et al. <em>JAMA Oncol</em>. 2021<br>49 hospitals—6 countries (France, Italy, South Korea, Spain, the United Kingdom, and the United States)</td>
<td rowspan="1" colspan="1">Multicenter, randomized, double-blind, placebo-controlled, clinical phase III trial.<br>Patients diagnosed with IDH1-mutant cholangiocarcinoma, histologically confirmed.</td>
<td rowspan="1" colspan="1">• A total of 187 patients were included and randomized 2:1. 126 patients received treatment with ivosidenib, and 61 were assigned to a placebo.<br>• Female patients are the majority, 65% for ivosidenib and 61% for placebo, respectively.<br>• 90% of patients treated with ivosidenib have intrahepatic cholangiocarcinoma, and 95% for the placebo.<br>• 93% and 92% had metastases for ivosidenib and placebo, respectively.</td>
<td rowspan="1" colspan="1">Patients were randomly assigned an ivosidenib (<em>n</em> = 124) or oral (500 mg) matched placebo (<em>n</em> = 61), once daily in continuous 28-day cycles (plus or minus 2 days), starting on cycle 1 day 1.<br>Ivosidenib compared with placebo.</td>
<td rowspan="1" colspan="1">Primary endpoint: PFS as determined by a blinded independent radiology center per RECIST, version 1.1.<br>Secondary endpoints: objective response rate, PFS per investigator assessment, safety and tolerability, and QoL.</td>
<td rowspan="1" colspan="1">Not indicated.</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table3-20420986251347376/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn2-20420986251347376"><p>DCR, Disease control rate; DOR, duration of response; FGFR2, fibroblast growth factor receptor 2; IDH1, isocitrate dehydrogenase 1; IQR, interquartile range; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QoL, quality of life.</p></div></div></section><section id="section15-20420986251347376"><h3 class="pmc_sec_title">Study characteristics</h3>
<p>The characteristics of the included studies are shown in <a href="#table3-20420986251347376" class="usa-link">Table 3</a>. In total, four studies were included for the systematic review, including two for pemigatinib<sup><a href="#bibr27-20420986251347376" class="usa-link" aria-describedby="bibr27-20420986251347376">27</a>,<a href="#bibr28-20420986251347376" class="usa-link" aria-describedby="bibr28-20420986251347376">28</a></sup> and one for futibatinib<sup>
<a href="#bibr29-20420986251347376" class="usa-link" aria-describedby="bibr29-20420986251347376">29</a>
</sup> and ivosidenib,<sup>
<a href="#bibr30-20420986251347376" class="usa-link" aria-describedby="bibr30-20420986251347376">30</a>
</sup> respectively. Of these, only one ivosidenib study features an RCT design, while the remaining three are observational studies. The sample size ranges from 31 to 187 patients diagnosed with stage 3/4 CCA with FGFR2 rearrangement or IDH-1 mutation. Furthermore, in the selected studies, women had a higher percentage than men, considering the three drugs included.</p>
<p>For pemigatinib, the data collected come from Asia, the United States, Europe, and the Middle East. The study is single-arm, multicenter, and phase II.<sup>
<a href="#bibr27-20420986251347376" class="usa-link" aria-describedby="bibr27-20420986251347376">27</a>
</sup> Patients in the first study were divided into three groups: with FGFR2 fusion or rearrangement, with other FGFR fusion or rearrangement, or without FGFR alteration. In the second included study,<sup>
<a href="#bibr28-20420986251347376" class="usa-link" aria-describedby="bibr28-20420986251347376">28</a>
</sup> 31 patients were enrolled, and all had an alteration of FGFR2.</p>
<p>For futibatinib,<sup>
<a href="#bibr29-20420986251347376" class="usa-link" aria-describedby="bibr29-20420986251347376">29</a>
</sup> there is a phase II, multicenter, single-arm study with a population of 103 people enrolled, from North America, Japan, Europe, Asia, and the Pacific with positive FGFR2 fusion or positive FGFR2 rearrangement.</p>
<p>For ivosidenib,<sup>
<a href="#bibr30-20420986251347376" class="usa-link" aria-describedby="bibr30-20420986251347376">30</a>
</sup> a total of 187 treated patients belonged to a single multicenter, double-blind, placebo-controlled phase III study. All enrolled patients have a histologically confirmed IDH1 mutation. In the informative <a href="#fig3-20420986251347376" class="usa-link">Figure 3</a>, the data for the three drugs are summarized.</p>
<figure class="fig xbox font-sm" id="fig3-20420986251347376"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365427_10.1177_20420986251347376-fig3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a83/12365427/49e0e6b80bd0/10.1177_20420986251347376-fig3.jpg" loading="lazy" height="422" width="724" alt="Figure 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3-20420986251347376/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Main drug characteristics.</p></figcaption></figure></section><section id="section16-20420986251347376"><h3 class="pmc_sec_title">Risk of bias of included studies</h3>
<p>The evaluation revealed that, although certain risks of bias were present—particularly in domains related to outcome measurement and missing data—the studies demonstrated several methodological strengths. Notably, the transparent selection of participants, the accurate classification of interventions, and the absence of selective outcome reporting represent robust methodological features that enhance the credibility of the findings. As such, the included studies offer a valid and informative contribution to the current understanding of the effectiveness of the interventions under investigation. Further details are provided in the <a href="https://journals.sagepub.com/doi/suppl/10.1177/20420986251347376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Materials</a>.</p></section><section id="section17-20420986251347376"><h3 class="pmc_sec_title">Safety profile of pemigatinib</h3>
<p>The systematic review considered two studies on pemigatinib, the first produced by Abou-Alfa et al., published in <em>Lancet Oncology</em> in 2020,<sup>
<a href="#bibr27-20420986251347376" class="usa-link" aria-describedby="bibr27-20420986251347376">27</a>
</sup> and the second by Shi et al., published in 2022<sup>
<a href="#bibr28-20420986251347376" class="usa-link" aria-describedby="bibr28-20420986251347376">28</a>
</sup> in <em>Cancer Medicine</em>.</p>
<p>FIGHT-202<sup>
<a href="#bibr25-20420986251347376" class="usa-link" aria-describedby="bibr25-20420986251347376">25</a>
</sup> is a multicenter, open-label, single-arm, multicohort, phase II study involving three cohorts of patients who received an oral dose of 13.5 mg of pemigatinib once daily for 21-day cycles. All patients had received prior systemic anticancer therapies for their advanced/metastatic disease. The median duration of treatment was 7.2 months (3.9–10.9) in patients with FGFR2 fusions or rearrangements, 1.4 months (1.0–6.1) in patients with other FGF/FGFR alterations, and 1.3 months (0.7–1.9) in patients without FGF/FGFR alterations.<sup>
<a href="#bibr27-20420986251347376" class="usa-link" aria-describedby="bibr27-20420986251347376">27</a>
</sup></p>
<p>FIGHT-202 was assessed for safety using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.<sup>
<a href="#bibr31-20420986251347376" class="usa-link" aria-describedby="bibr31-20420986251347376">31</a>
</sup> In this study, safety was assessed in three stages: at screening, during treatment (days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles), at the end of treatment, and during follow-up (30 days after stopping treatment). Patients in the three cohorts (<em>n</em> = 146) experienced hyperphosphatemia as the most common AE, which occurred in <em>n</em> = 88 (60%). This AE occurred with a median time to onset of 15 days 95% (CI 8–47) and was treated with a low-phosphate diet, concomitant phosphate binders (27 patients (18%)), diuretics (1 patient (1%)), with dose reduction (1 patient (1%)) and dose interruption (two patients (1%)). Hypophosphatemia occurred in 33 (23%) of 146 patients and was the most common grade 3 or worse (10 (7%)) treatment-related AE. Mean changes in phosphate concentration from baseline decreased after day 15 of cycle 1; 1,25(OH)2D3 and parathyroid hormone concentrations followed similar patterns, albeit with some reversal in parathyroid hormone concentrations at longer treatment durations. The percentage of patients with 1,25(OH)2D3 levels below normal (&lt;18 to 86 pg/mL) increased from 17 (15%) of 117 at baseline to 63 (79%) of 80 on day 1 of cycle 5. The percentage of patients with lower-than-normal parathyroid hormone levels (&lt;10 to 65 pg/mL) increased from 15 (11%) of 137 at baseline to 20 (22%) of 89 on day 1 of cycle 5. Other common grade 1–4 AEs were alopecia, diarrhea, fatigue, and dysgeusia, with an incidence of ⩾40%. In all, 93 (64%) patients experienced grade 3 or worse AEs. The most frequent grade 3 or worse AEs (regardless of cause) were hypophosphatemia (18 (12%)), arthralgia (9 (6%)), stomatitis (8 (5%)), hyponatremia (8 (5%)), abdominal pain (7 (5%)), and fatigue (7 (5%)). Other clinically notable AEs include nail toxicity and serum retinal detachment. The former was experienced by 62 (42%) of 146 patients (3 (2%) grade ⩾3) and occurred with a median time to onset of 6 months. Five (3%) of 146 patients had dose reductions, and six (4%) had dose interruptions due to nail toxicity. Serum retinal detachment, due to accumulation of subretinal fluid, occurred in six (4%) of 146 patients; all events were grade 1 or 2. One (1%) of 146 patients had a dose interruption due to this AE.<sup>
<a href="#bibr27-20420986251347376" class="usa-link" aria-describedby="bibr27-20420986251347376">27</a>
</sup></p>
<p>The second study of pemigatinib<sup>
<a href="#bibr28-20420986251347376" class="usa-link" aria-describedby="bibr28-20420986251347376">28</a>
</sup> is a multicenter, single-arm, phase II study that was conducted in 14 hospitals in China. The dose of pemigatinib administered to patients corresponds to 13.5 mg orally once a day, with a cycle of 21 days. Patients treated with pemigatinib, belonging to a single cohort, previously received systemic therapy for advanced and metastatic disease. AEs were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events v5.0.<sup>
<a href="#bibr32-20420986251347376" class="usa-link" aria-describedby="bibr32-20420986251347376">32</a>
</sup></p>
<p>The most common AEs were hyperphosphatemia (77.4%), of which one (3.2%) was grade ⩾ 3, dry mouth (54.8%), and alopecia (54.8%). Serious AEs occurred in three (9.7%) patients: rectal polyps, abnormal liver function, and biliary tract infection. A total of four patients (12.9%) had dose interruption due to hypercalcemia, pain in the extremity, abnormal liver function, and vomiting, respectively.</p>
<p>In this study, as in FIGHT-202, both nail toxicity occurred in 16 patients (51.6%), and retinal detachment occurred in 3 (9.7%) patients. Hypophosphatasemia occurred in 7 (22.6%) patients, and changes in 25-hydroxyvitamin D and blood calcium were modest for most patients during treatment.<sup>
<a href="#bibr28-20420986251347376" class="usa-link" aria-describedby="bibr28-20420986251347376">28</a>
</sup> The median PFS, calculated using Kaplan–Meier estimates, was 6.9 months (95% CI: 6.2–9.6) in patients with FGFR2 rearrangements. Durable responses were observed in 35.5% of patients with FGFR2 alterations, with a complete response in 2.8% and a partial response in 32.7%. Data from both studies suggest that QoL, assessed using validated tools such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EuroQol 5-Dimension 5-Level (EQ-5D-5L)—which measure parameters including physical, functional, and emotional well-being—was preserved through a proactive approach to AE management. This approach allowed many patients to continue treatment without compromising their daily activities.</p></section><section id="section18-20420986251347376"><h3 class="pmc_sec_title">Safety profile of futibatinib</h3>
<p>FOENIX-CCA2<sup>
<a href="#bibr29-20420986251347376" class="usa-link" aria-describedby="bibr29-20420986251347376">29</a>
</sup> is a multinational, open-label, phase II study conducted at 47 centers in 13 countries. Enrolled patients received an oral futibatinib dose of 20 mg once daily continuously.</p>
<p>The safety profile of the drug was evaluated from the first dose of futibatinib until 30 days after the last dose or until starting a new agent.</p>
<p>AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.<sup>
<a href="#bibr31-20420986251347376" class="usa-link" aria-describedby="bibr31-20420986251347376">31</a>
</sup> The safety profiles were evaluated from the first dose of futibatinib administration, and the observation time was up to 30 days after the last dose or, alternatively, until the start of a new chemotherapy agent.</p>
<p>The AEs that occurred were of variable grade, in the article, with a grade ranging from 1 to 4. Hyperphosphatemia occurred in 85% of patients, alopecia in 33%, dry mouth in 30%, diarrhea in 28%, dry skin in 27%, and fatigue in 25% of cases. Grade three adverse reactions occurred, of which hyperphosphatemia was the most common, approximately 30% of patients under treatment, defined as a serum phosphate level equal to or greater than 7 mg per deciliter. In patients undergoing treatment, the occurrence of hyperphosphatemia occurred with a median of 5 days and was treated with a diet based on hypophosphate in 78% of cases, with dose reduction or interruptions in administration; however, no one discontinued treatment due to this adverse reaction, which on average resolved in 7 days. When serum phosphate levels were ⩾5.5 mg/dL, patients temporarily interrupted treatment. This was accompanied using phosphate-lowering therapies, such as phosphate binders, to control serum phosphate levels effectively.</p>
<p>Toxic effects that occur when FGFR inhibitors are administered occurred in 47% of patients with nail disorders and 8% with retinal disorders.</p>
<p>Increased alanine aminotransferase level was the only grade 4 reaction occurring in 1% of cases. Overall, treatment-related AEs led to dose interruptions in 52 patients (50%) and dose reductions in 56 patients (54%). They have not been reported as grade 5.<sup>
<a href="#bibr29-20420986251347376" class="usa-link" aria-describedby="bibr29-20420986251347376">29</a>
</sup> The OS associated with futibatinib treatment was reported with a median value of 21.7 months and a 12-month survival rate of 72%. The median PFS was 9.0 months, with a 6-month progression-free survival rate of 66% and a 12-month rate of 40%. These data indicate that futibatinib significantly prolongs survival compared to the SoC.</p>
<p>In patients experiencing AEs, futibatinib treatment was managed gradually. Initially, the dose was reduced to 16 mg per day. If AEs persisted, a further reduction to 12 mg per day was implemented. Ultimately, treatment was discontinued if AEs remained unresolved. Futibatinib demonstrated a robust objective response rate (ORR) of 42% (95% CI, 32–52) in patients with advanced iCCA. The median duration of response (DOR) was 9.7 months (95% CI, 7.6–17.1), reflecting the durability of clinical benefit in this molecularly defined population. Notably, 72% of patients maintained their response for at least 6 months, and 14% experienced responses lasting 12 months or longer. These data highlight futibatinib’s sustained anti-tumor activity in a setting where therapeutic options are otherwise limited and often poorly tolerated.</p></section><section id="section19-20420986251347376"><h3 class="pmc_sec_title">Safety profile of ivosidenib</h3>
<p>ClarIDHy<sup>
<a href="#bibr30-20420986251347376" class="usa-link" aria-describedby="bibr30-20420986251347376">30</a>
</sup> is a multicenter, randomized, double-blind, placebo-controlled phase III study. The patients included in this study came from 49 hospitals in 6 different countries for a total of 126 treated with ivosidenib and 61 with placebo. All patients had histologically confirmed advanced CCA with IDH1 mutation and had been treated with prior therapy.</p>
<p>In the study, ivosidenib or placebo, randomized 2:1, was administered orally once daily for a continuous 28-day cycle. Treatment safety and tolerability were assessed from the first dose, and treatment-emergent AEs were classified by severity and type according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.03.<sup>
<a href="#bibr31-20420986251347376" class="usa-link" aria-describedby="bibr31-20420986251347376">31</a>
</sup> Grade 1–5 reactions were identified in the study for both protocols: ivosidenib or placebo.</p>
<p>The most common grade 3 AE was ascites, which occurred in 11 (9%) patients who received ivosidenib and 4 (7%) patients who received placebo. In addition, grade 3 or higher anemia was more common in 8 (7%) patients versus 0 patients; increased blood bilirubin levels in 7 patients (6%) versus 1 patient (2%), and hyponatremia in 7 patients (6%) versus 6 patients (10%).</p>
<p>Another adverse reaction that occurred in 12 patients (10%) treated with ivosidenib and in 2 patients (3%) treated with placebo was a prolongation of the QT interval on the electrocardiogram.</p>
<p>In total, only 5 patients (4%) in the ivosidenib group had serious AEs that led to a dose reduction, while 9 patients (7%) had to completely discontinue treatment. Treatment discontinuation, but not dose reduction, occurred with placebo in 5 (8%) of patients.<sup>
<a href="#bibr30-20420986251347376" class="usa-link" aria-describedby="bibr30-20420986251347376">30</a>
</sup> This study shows the positive outcome of treatment with ivosidenib; in fact, the survival rate at 12 months of therapy was 43% versus 36% for the drug. Furthermore, according to the results published by Zhu et al., the median PFS was statistically significantly higher in the ivosidenib group than in the placebo group (2.7 months vs 1.4 months (HR, 0.37; 95% CI, 0.25–0.54; <em>p</em> &lt; 0.0001)), with a reduction in the risk of progression or death of 63%.<sup>
<a href="#bibr30-20420986251347376" class="usa-link" aria-describedby="bibr30-20420986251347376">30</a>
</sup></p>
<p>In patients experiencing grade ⩾3 AEs related to drug administration, such as QT interval prolongation, significant hepatic toxicity (e.g., elevated transaminases or serum bilirubin), or severe gastrointestinal effects (including persistent nausea, vomiting, or diarrhea), the dose was reduced to 250 mg daily or temporarily suspended until resolution or improvement of the event. These measures positively impacted health-related quality of life (HRQoL), as demonstrated by outcomes from the EORTC QLQ-C30 (a QoL questionnaire for oncology patients) and the EORTC QLQ-BIL21 (a questionnaire specific to biliary tract cancers).<sup>
<a href="#bibr30-20420986251347376" class="usa-link" aria-describedby="bibr30-20420986251347376">30</a>
</sup> In ClarIDHy trial, it is reported a modest ORR of 2%. Although the median DOR was not specifically reported, the clinical benefit of ivosidenib was evident through significant improvement in PFS and disease stabilization rates compared to placebo.</p></section></section><section id="section20-20420986251347376"><h2 class="pmc_sec_title">Discussion</h2>
<section id="section21-20420986251347376"><h3 class="pmc_sec_title">Relevance to patient care and clinical practice</h3>
<p>This review provides a comprehensive update on the treatment of CCA, incorporating evidence from clinical trials published up to July 2023. A key advancement discussed is the integration of targeted therapies for patients with specific genetic alterations, such as FGFR2 fusions or rearrangements and IDH1 mutations. This marks a significant shift from traditional first- and second-line treatments toward more personalized, genomics-based approaches.</p>
<p>The diagnosis of CCA remains challenging. Many patients are diagnosed only upon the onset of symptoms such as jaundice, abdominal pain, anorexia, weight loss, and night sweats. Due to the nonspecific nature of these symptoms, diagnosis often occurs incidentally through imaging studies conducted for other causes of symptomatic biliary obstruction.<sup>
<a href="#bibr33-20420986251347376" class="usa-link" aria-describedby="bibr33-20420986251347376">33</a>
</sup> Recent analyses suggest that 20–40% of patients with intrahepatic CCA are diagnosed incidentally.<sup>
<a href="#bibr34-20420986251347376" class="usa-link" aria-describedby="bibr34-20420986251347376">34</a>
</sup> Currently, there is no standardized protocol for prevention and early detection. However, screening indicators have been proposed. For example, the American Association for the Study of Liver Diseases (AASLD) recommends annual magnetic resonance imaging or magnetic resonance cholangiopancreatography, with or without serum biomarkers, for patients with primary sclerosing cholangitis.<sup>
<a href="#bibr35-20420986251347376" class="usa-link" aria-describedby="bibr35-20420986251347376">35</a>
</sup></p>
<p>From a clinical perspective, incorporating genetic testing for FGFR2 and IDH1 alterations into routine diagnostic and therapeutic workflows is essential. Identification of these biomarkers enables healthcare providers to personalize treatment strategies, improve efficacy, and reduce reliance on less effective standard therapies. These findings emphasize the potential of targeting specific genetic alterations to achieve more tailored and effective treatment strategies, moving beyond the limitations of conventional chemotherapy.</p>
<p>From a clinical perspective, incorporating genetic testing for FGFR2 and IDH1 alterations into routine diagnostic and therapeutic workflows is essential. Identifying these biomarkers enables healthcare professionals to personalize treatment strategies, enhance efficacy, and reduce reliance on less effective standard therapies. These findings underscore the potential of targeting specific genetic alterations to achieve more tailored and effective treatment strategies, overcoming the limitations of conventional chemotherapy.</p>
<p>One of the main distinguishing features of targeted therapies such as pemigatinib, futibatinib, and ivosidenib is their favorable tolerability profile compared to conventional chemotherapy. For pemigatinib, the most frequently reported AE was hyperphosphatemia, occurring in approximately 60% of patients in the FIGHT-202 trial, and up to 26% of grade ⩾3 cases in the Chinese cohort. Despite its high incidence, hyperphosphatemia was largely manageable with dietary modifications, phosphate binders, and dose adjustments, and rarely led to treatment discontinuation. Other common AEs included stomatitis, fatigue, and ocular toxicities, generally of mild severity. Serious treatment-related AEs were uncommon, and no deaths were attributed to the drug.</p>
<p>For futibatinib, the most common AE was also hyperphosphatemia, observed in 85% of patients, with 30% of cases being grade 3. This was generally successfully managed with hypophosphatemia therapy, temporary treatment interruptions, or dose reductions. All grade 3 cases resolved within a median of 7 days. Ocular events, such as retinal disorders and cataracts, were reported in 8% and 4% of patients, respectively, all of which were of mild or moderate severity.</p>
<p>Ivosidenib demonstrated an even more favorable safety profile in the phase III ClarIDHy trial, with a low incidence of treatment-related serious AEs (2%) and a tolerability profile comparable to placebo. Common AEs such as nausea, fatigue, and ascites were reported at manageable levels. Importantly, QTc interval prolongation, a class effect of IDH1 inhibitors, was infrequent and clinically manageable with ECG monitoring. No deterioration in HRQoL was observed compared to placebo, further supporting its suitability for long-term administration.</p>
<p>Across all studies, the low rate of treatment discontinuation due to toxicity and the absence of treatment-related mortality underscore the clinical feasibility of prolonged therapy with these agents. These findings are particularly relevant given the limited therapeutic options and the frailty of patients with advanced or metastatic CCA. A table of the various AEs compared is present in the <a href="https://journals.sagepub.com/doi/suppl/10.1177/20420986251347376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Materials (Table S1)</a>.</p>
<p>An important advantage of these agents is their oral administration, which provides significant logistical and QoL benefits for patients with advanced CCA. Unlike standard chemotherapy regimens that require repeated hospital-based infusions, these drugs can be taken at home, reducing the burden of hospital visits and facilitating integration into daily life.</p>
<p>This administration mode is especially beneficial for patients with compromised general conditions or functional limitations, offering greater autonomy in treatment management. Furthermore, oral therapies have been shown to improve patients’ perceived sense of control, reduce the psychological stress associated with treatment, and enhance adherence when supported by appropriate education and clinical follow-up.<sup><a href="#bibr36-20420986251347376" class="usa-link" aria-describedby="bibr36-20420986251347376">36</a>,<a href="#bibr37-20420986251347376" class="usa-link" aria-describedby="bibr37-20420986251347376">37</a></sup></p>
<p>The review acknowledges several limitations. Among these is the overall heterogeneity in the methodological quality of the included studies, particularly in outcome measurement and control of confounding factors, which are notoriously complex in observational research. However, the overall assessment did not reveal biases sufficient to invalidate the results. The number of study participants for the three drugs remains limited and not fully representative of the general patient population. This is partly due to diagnostic challenges and the relatively rare incidence of CCA. The limited number of studies and the lack of control arms in many of them weaken the strength of the evidence. For pemigatinib, only two single-arm studies met the inclusion criteria. For futibatinib, only one non-comparative study was included. For ivosidenib, only one study met the criteria—the only RCT in the review, which included a placebo comparison. In addition, the predominance of female participants in some studies may limit generalizability.</p>
<p>Further evidence and real-world data are needed to better understand the optimal use of pemigatinib, futibatinib, and ivosidenib in patients with locally advanced or metastatic CCA. A multidisciplinary team is essential for the effective management of FGFR inhibitor therapy. Pharmacists play a central role not only in drug procurement but also in monitoring adherence, managing drug interactions, ensuring prescription continuity, and minimizing financial toxicity. In parallel, nurses and physician assistants monitor patients during outpatient visits and through regular phone follow-ups, supporting clinical management and AE monitoring. Optometrists are critical for the early identification and management of ocular toxicities associated with FGFR inhibitors. Dietitians provide essential nutritional support, particularly in managing hyperphosphatemia through low-phosphate diets. Nurse coordinators and navigators serve as consistent points of contact for patients throughout therapy, facilitating communication within the care team. Social workers further support patients’ overall well-being by offering psychosocial assistance and practical resources.</p>
<p>It is important to note that multidisciplinary team structures may vary across institutions. Clearly defining roles and responsibilities is crucial to avoid gaps in care and ensure coordinated patient management, while maintaining regular communication between patients and their primary care providers to ensure continuous and integrated support.</p>
<p>Addressing these organizational aspects would contribute to more consistent safety data collection and enhance our understanding of individual responses to targeted therapies. Overall, this review offers valuable insights into the benefits and challenges of targeted treatments, reinforcing the role of precision medicine in improving outcomes for patients with cholangiocarcinoma.</p></section></section><section id="section22-20420986251347376"><h2 class="pmc_sec_title">Conclusion</h2>
<p>This is the latest and among the first systematic reviews of the literature, including recent trials on pemigatinib, futibatinib, and ivosidenib. The studies included are phase II and III, with only one concerning ivosidenib being randomized, double-blind. The choice of these three drugs is due to careful research into what are becoming effective second-line therapies for CCA.</p>
<p>In the future, new trials are being advanced for pemigatinib. The objective is to evaluate the efficacy and safety of pemigatinib compared to chemotherapy with gemcitabine plus cisplatin in the first-line treatment of participants with unresectable or metastatic CCA with FGFR2 rearrangement. For futibatinib, an ongoing, multinational, randomized, open-label phase II study confirms the clinical benefit of 20 mg futibatinib and evaluates the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements. A phase III research study is underway for ivosidenib to consolidate data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced or metastatic CCA.</p>
<p>In conclusion, based on the evidence of the present analysis, pemigatinib, futibatinib, and ivosidenib may be a useful treatment option for selected patients with advanced cholangiocarcinoma. The risk of developing grade 3 and 4 adverse reactions is limited, and these AEs that occurred during the trial were easily contained. A thorough evaluation of the studies included in this systematic review highlighted effective patient management. The AEs for pemigatinib, futibatinib, and ivosidenib were handled optimally, with severe reactions addressed through dose adjustments or temporary therapy suspension when necessary, enabling patients to continue treatment without permanent discontinuation. Future studies should aim to analyze the effects of these new target therapies with larger population arms, to broaden knowledge of safety data and modulate dosing. It is hoped that this review can be of real help to all healthcare professionals who have to treat this rare disease, simply by providing a broad view of the adverse reactions reported for drugs/genomic alterations.</p></section><section id="section23-20420986251347376"><h2 class="pmc_sec_title">Supplemental Material</h2>
<section class="sm xbox font-sm" id="suppl1-20420986251347376"><div class="caption p"><span>sj-docx-1-taw-10.1177_20420986251347376 – Supplemental material for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365427/bin/sj-docx-1-taw-10.1177_20420986251347376.docx" data-ga-action="click_feat_suppl" class="usa-link">sj-docx-1-taw-10.1177_20420986251347376.docx</a><sup> (31KB, docx) </sup>
</div></div>
<p>Supplemental material, sj-docx-1-taw-10.1177_20420986251347376 for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review by Giulia Matranga, Anna Carollo, Miriam Alaimo, Sofia Cutaia, Sergio Rizzo and Alessio Provenzani in Therapeutic Advances in Drug Safety</p></section><section class="sm xbox font-sm" id="suppl2-20420986251347376"><div class="caption p"><span>sj-docx-2-taw-10.1177_20420986251347376 – Supplemental material for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365427/bin/sj-docx-2-taw-10.1177_20420986251347376.docx" data-ga-action="click_feat_suppl" class="usa-link">sj-docx-2-taw-10.1177_20420986251347376.docx</a><sup> (97.5KB, docx) </sup>
</div></div>
<p>Supplemental material, sj-docx-2-taw-10.1177_20420986251347376 for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review by Giulia Matranga, Anna Carollo, Miriam Alaimo, Sofia Cutaia, Sergio Rizzo and Alessio Provenzani in Therapeutic Advances in Drug Safety</p></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>None.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn3">
<p><strong>ORCID iDs:</strong> Anna Carollo <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a83/12365427/03e617e2a807/10.1177_20420986251347376-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0009-0008-1931-8330" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0009-0008-1931-8330</a></p>
<p>Alessio Provenzani <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a83/12365427/03e617e2a807/10.1177_20420986251347376-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0000-0001-7132-000X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0000-0001-7132-000X</a></p>
</div>
<div class="fn p" id="fn4"><p><strong>Supplemental material:</strong> Supplemental material for this article is available online.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Giulia Matranga, Master in Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, and Real-World Evidence, University of Verona, Verona, Italy.</p>
<p>Anna Carollo, Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy.</p>
<p>Miriam Alaimo, Regional Pharmacovigilance Center, University of Messina, Messina, Italy.</p>
<p>Sofia Cutaia, Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy.</p>
<p>Sergio Rizzo, Medical Oncology Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Palermo, Italy.</p>
<p>Alessio Provenzani, Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), Via E.Tricomi n. 5, Palermo 90127, Italy.</p></section><section id="section25-20420986251347376"><h2 class="pmc_sec_title">Declarations</h2>
<section id="fn-group2" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn5"><p><strong>Ethics approval and consent to participate:</strong> Not applicable.</p></div>
<div class="fn p" id="fn6"><p><strong>Consent for publication:</strong> Not applicable.</p></div>
<div class="fn p" id="fn7">
<p><strong>Author contributions:</strong>
<strong>Giulia Matranga:</strong> Formal analysis; Investigation; Methodology; Writing – original draft; Writing – review &amp; editing.</p>
<p><strong>Anna Carollo:</strong> Conceptualization; Data curation; Supervision; Validation; Writing – review &amp; editing.</p>
<p><strong>Miriam Alaimo:</strong> Investigation; Visualization; Writing – review &amp; editing.</p>
<p><strong>Sofia Cutaia:</strong> Conceptualization; Validation; Writing – review &amp; editing.</p>
<p><strong>Sergio Rizzo:</strong> Conceptualization; Project administration; Supervision; Validation; Writing – review &amp; editing.</p>
<p><strong>Alessio Provenzani:</strong> Conceptualization; Data curation; Methodology; Validation; Writing – review &amp; editing.</p>
</div>
<div class="fn p" id="fn8"><p><strong>Funding:</strong> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Italian Ministry of Health, Rome, Italy.</p></div>
<div class="fn p" id="fn9"><p><strong>Competing interests:</strong> The authors declare that there is no conflict of interest.</p></div>
<div class="fn p" id="fn10"><p><strong>Availability of data and materials:</strong> All data relevant to the study are included in the article or available upon request.</p></div>
</div></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bibr1-20420986251347376">
<span class="label">1.</span><cite>
Banales JM, Cardinale V, Carpino G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol
2016; 13: 261–280.
</cite> [<a href="https://doi.org/10.1038/nrgastro.2016.51" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27095655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Gastroenterol%20Hepatol&amp;title=Cholangiocarcinoma:%20current%20knowledge%20and%20future%20perspectives%20consensus%20statement%20from%20the%20European%20Network%20for%20the%20Study%20of%20Cholangiocarcinoma%20(ENS-CCA)&amp;author=JM%20Banales&amp;author=V%20Cardinale&amp;author=G%20Carpino&amp;volume=13&amp;publication_year=2016&amp;pages=261-280&amp;pmid=27095655&amp;doi=10.1038/nrgastro.2016.51&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr2-20420986251347376">
<span class="label">2.</span><cite>
Khan SA, Tavolari S, Brandi G.
Cholangiocarcinoma: epidemiology and risk factors. Liver Int
2019; 39:19–31.
</cite> [<a href="https://doi.org/10.1111/liv.14095" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30851228/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Int&amp;title=Cholangiocarcinoma:%20epidemiology%20and%20risk%20factors&amp;author=SA%20Khan&amp;author=S%20Tavolari&amp;author=G.%20Brandi&amp;volume=39&amp;publication_year=2019&amp;pages=19-31&amp;pmid=30851228&amp;doi=10.1111/liv.14095&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr3-20420986251347376">
<span class="label">3.</span><cite>
Zhang X, Cai Y, Xiong X, et al. Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. Intractable Rare Dis Res
2022; 11: 161–172.
</cite> [<a href="https://doi.org/10.5582/irdr.2022.01109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9709616/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36457589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Intractable%20Rare%20Dis%20Res&amp;title=Comparison%20of%20current%20guidelines%20and%20consensus%20on%20the%20management%20of%20patients%20with%20cholangiocarcinoma:%202022%20update&amp;author=X%20Zhang&amp;author=Y%20Cai&amp;author=X%20Xiong&amp;volume=11&amp;publication_year=2022&amp;pages=161-172&amp;pmid=36457589&amp;doi=10.5582/irdr.2022.01109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr4-20420986251347376">
<span class="label">4.</span><cite>
Massironi S, Pilla L, Elvevi A, et al. New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells
2020; 9: 688.
</cite> [<a href="https://doi.org/10.3390/cells9030688" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7140695/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32168869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=New%20and%20emerging%20systemic%20therapeutic%20options%20for%20advanced%20cholangiocarcinoma&amp;author=S%20Massironi&amp;author=L%20Pilla&amp;author=A%20Elvevi&amp;volume=9&amp;publication_year=2020&amp;pages=688&amp;pmid=32168869&amp;doi=10.3390/cells9030688&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr5-20420986251347376">
<span class="label">5.</span><cite>
Carnevale G, Carpino G, Cardinale V, et al. Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells. Sci Rep
2017; 7: 14419.
</cite> [<a href="https://doi.org/10.1038/s41598-017-14838-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5663931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29089545/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Activation%20of%20Fas/FasL%20pathway%20and%20the%20role%20of%20c-FLIP%20in%20primary%20culture%20of%20human%20cholangiocarcinoma%20cells&amp;author=G%20Carnevale&amp;author=G%20Carpino&amp;author=V%20Cardinale&amp;volume=7&amp;publication_year=2017&amp;pages=14419&amp;pmid=29089545&amp;doi=10.1038/s41598-017-14838-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr6-20420986251347376">
<span class="label">6.</span><cite>
Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol
2019; 71: 104–114.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2019.03.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30910538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Global%20trends%20in%20mortality%20from%20intrahepatic%20and%20extrahepatic%20cholangiocarcinoma&amp;author=P%20Bertuccio&amp;author=M%20Malvezzi&amp;author=G%20Carioli&amp;volume=71&amp;publication_year=2019&amp;pages=104-114&amp;pmid=30910538&amp;doi=10.1016/j.jhep.2019.03.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr7-20420986251347376">
<span class="label">7.</span><cite>
Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol
2014; 25: 391–398.
</cite> [<a href="https://doi.org/10.1093/annonc/mdt540" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24351397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Cisplatin%20and%20gemcitabine%20for%20advanced%20biliary%20tract%20cancer:%20a%20meta-analysis%20of%20two%20randomised%20trials&amp;author=JW%20Valle&amp;author=J%20Furuse&amp;author=M%20Jitlal&amp;volume=25&amp;publication_year=2014&amp;pages=391-398&amp;pmid=24351397&amp;doi=10.1093/annonc/mdt540&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr8-20420986251347376">
<span class="label">8.</span><cite>
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med
2010; 362: 1273–1281.
</cite> [<a href="https://doi.org/10.1056/NEJMoa0908721" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20375404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Cisplatin%20plus%20gemcitabine%20versus%20gemcitabine%20for%20biliary%20tract%20cancer&amp;author=J%20Valle&amp;author=H%20Wasan&amp;author=DH%20Palmer&amp;volume=362&amp;publication_year=2010&amp;pages=1273-1281&amp;pmid=20375404&amp;doi=10.1056/NEJMoa0908721&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr9-20420986251347376">
<span class="label">9.</span><cite>
Oh D-Y, He AR, Qin S, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol
2022; 33: S1462–S1463.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=78P%20Updated%20overall%20survival%20(OS)%20from%20the%20phase%20III%20TOPAZ-1%20study%20of%20durvalumab%20(D)%20or%20placebo%20(PBO)%20plus%20gemcitabine%20and%20cisplatin%20(+%20GC)%20in%20patients%20(pts)%20with%20advanced%20biliary%20tract%20cancer%20(BTC)&amp;author=D-Y%20Oh&amp;author=AR%20He&amp;author=S%20Qin&amp;volume=33&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr10-20420986251347376">
<span class="label">10.</span><cite>
Lamarca A, Palmer DH, Wasan HS, et al. ABC-06 | a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol
2019; 37: 4003–4003.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=ABC-06%20%7C%20a%20randomised%20phase%20III,%20multi-centre,%20open-label%20study%20of%20active%20symptom%20control%20(ASC)%20alone%20or%20ASC%20with%20oxaliplatin/5-FU%20chemotherapy%20(ASC+mFOLFOX)%20for%20patients%20(pts)%20with%20locally%20advanced/metastatic%20biliary%20tract%20cancers%20(ABC)%20previously-treated%20with%20cisplatin/gemcitabine%20(CisGem)%20chemotherapy&amp;author=A%20Lamarca&amp;author=DH%20Palmer&amp;author=HS%20Wasan&amp;volume=37&amp;publication_year=2019&amp;pages=4003-4003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr11-20420986251347376">
<span class="label">11.</span><cite>
Kendre G, Murugesan K, Brummer T, et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol
2023; 78: 614–626.
</cite> [<a href="https://doi.org/10.1016/j.jhep.2022.11.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36528236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Charting%20co-mutation%20patterns%20associated%20with%20actionable%20drivers%20in%20intrahepatic%20cholangiocarcinoma&amp;author=G%20Kendre&amp;author=K%20Murugesan&amp;author=T%20Brummer&amp;volume=78&amp;publication_year=2023&amp;pages=614-626&amp;pmid=36528236&amp;doi=10.1016/j.jhep.2022.11.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr12-20420986251347376">
<span class="label">12.</span><cite>
Rimassa L, Brandi G, Niger M, et al. Diagnosis and treatment of cholangiocarcinoma in Italy: a Delphi consensus statement. Crit Rev Oncol Hematol
2023; 192: 104146.
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2023.104146" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37777074/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Crit%20Rev%20Oncol%20Hematol&amp;title=Diagnosis%20and%20treatment%20of%20cholangiocarcinoma%20in%20Italy:%20a%20Delphi%20consensus%20statement&amp;author=L%20Rimassa&amp;author=G%20Brandi&amp;author=M%20Niger&amp;volume=192&amp;publication_year=2023&amp;pages=104146&amp;pmid=37777074&amp;doi=10.1016/j.critrevonc.2023.104146&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr13-20420986251347376">
<span class="label">13.</span><cite>
PEMAZYRE (pemigatinib) [Internet]. [Cited 23 March 2025], <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf</a> (2022, accessed 24 July 2023).</cite>
</li>
<li id="bibr14-20420986251347376">
<span class="label">14.</span><cite>
Patel TH, Marcus L, Horiba MN, et al. FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clin Cancer Res
2023; 29: 838–842.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-2036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9991984/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36206041/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=FDA%20approval%20summary:%20pemigatinib%20for%20previously%20treated,%20unresectable%20locally%20advanced%20or%20metastatic%20cholangiocarcinoma%20with%20FGFR2%20fusion%20or%20other%20rearrangement&amp;author=TH%20Patel&amp;author=L%20Marcus&amp;author=MN%20Horiba&amp;volume=29&amp;publication_year=2023&amp;pages=838-842&amp;pmid=36206041&amp;doi=10.1158/1078-0432.CCR-22-2036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr15-20420986251347376">
<span class="label">15.</span><cite>
Hoy SM.
Pemigatinib: first approval. Drugs
2020; 80: 923–929.
</cite> [<a href="https://doi.org/10.1007/s40265-020-01330-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32472305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Pemigatinib:%20first%20approval&amp;author=SM.%20Hoy&amp;volume=80&amp;publication_year=2020&amp;pages=923-929&amp;pmid=32472305&amp;doi=10.1007/s40265-020-01330-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr16-20420986251347376">
<span class="label">16.</span><cite>
Uson PLS, Bearss J, Babiker HM, et al. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma. Expert Opin Drug Saf
2023; 22: 637–641.
</cite> [<a href="https://doi.org/10.1080/14740338.2023.2227561" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37363820/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Drug%20Saf&amp;title=A%20drug%20safety%20evaluation%20of%20pemigatinib%20for%20advanced%20cholangiocarcinoma&amp;author=PLS%20Uson&amp;author=J%20Bearss&amp;author=HM%20Babiker&amp;volume=22&amp;publication_year=2023&amp;pages=637-641&amp;pmid=37363820&amp;doi=10.1080/14740338.2023.2227561&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr17-20420986251347376">
<span class="label">17.</span><cite>
Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res
2020; 80: 4986–4997.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-19-2568" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32973082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Futibatinib%20is%20a%20novel%20irreversible%20FGFR%201%E2%80%934%20inhibitor%20that%20shows%20selective%20antitumor%20activity%20against%20FGFR-deregulated%20tumors&amp;author=H%20Sootome&amp;author=H%20Fujita&amp;author=K%20Ito&amp;volume=80&amp;publication_year=2020&amp;pages=4986-4997&amp;pmid=32973082&amp;doi=10.1158/0008-5472.CAN-19-2568&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr18-20420986251347376">
<span class="label">18.</span><cite>
Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem
2019; 14: 494–500.
</cite> [<a href="https://doi.org/10.1002/cmdc.201800719" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30600916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ChemMedChem&amp;title=TAS-120%20cancer%20target%20binding:%20defining%20reactivity%20and%20revealing%20the%20first%20fibroblast%20growth%20factor%20receptor%201%20(FGFR1)%20irreversible%20structure&amp;author=M%20Kalyukina&amp;author=Y%20Yosaatmadja&amp;author=MJ%20Middleditch&amp;volume=14&amp;publication_year=2019&amp;pages=494-500&amp;pmid=30600916&amp;doi=10.1002/cmdc.201800719&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr19-20420986251347376">
<span class="label">19.</span><cite>
LYTGOBI (futibatinib) [Internet]. [Cited 23 March 2025], <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf</a> (2022, accessed 24 July 2023).</cite>
</li>
<li id="bibr20-20420986251347376">
<span class="label">20.</span><cite>
Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors. Ann Oncol
2020; 31: 1405–1412.
</cite> [<a href="https://doi.org/10.1016/j.annonc.2020.06.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9743148/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32622884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Phase%20I,%20first-in-human%20study%20of%20futibatinib,%20a%20highly%20selective,%20irreversible%20FGFR1%E2%80%934%20inhibitor%20in%20patients%20with%20advanced%20solid%20tumors&amp;author=R%20Bahleda&amp;author=F%20Meric-Bernstam&amp;author=L%20Goyal&amp;volume=31&amp;publication_year=2020&amp;pages=1405-1412&amp;pmid=32622884&amp;doi=10.1016/j.annonc.2020.06.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr21-20420986251347376">
<span class="label">21.</span><cite>
Gao L, Yamamiya I, Pinti M, et al. A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Clin Transl Sci
2023; 16: 1713–1724.
</cite> [<a href="https://doi.org/10.1111/cts.13585" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10499415/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37553804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Transl%20Sci&amp;title=A%20phase%20I,%20open-label,%20single-dose%20study%20to%20evaluate%20the%20effect%20of%20hepatic%20impairment%20on%20the%20pharmacokinetics%20and%20safety%20of%20futibatinib&amp;author=L%20Gao&amp;author=I%20Yamamiya&amp;author=M%20Pinti&amp;volume=16&amp;publication_year=2023&amp;pages=1713-1724&amp;pmid=37553804&amp;doi=10.1111/cts.13585&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr22-20420986251347376">
<span class="label">22.</span><cite>
Boscoe AN, Rolland C, Kelley RK.
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol
2019; 10: 751–65.</cite> [<a href="https://doi.org/10.21037/jgo.2019.03.10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6657309/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31392056/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Gastrointest%20Oncol&amp;title=Frequency%20and%20prognostic%20significance%20of%20isocitrate%20dehydrogenase%201%20mutations%20in%20cholangiocarcinoma:%20a%20systematic%20literature%20review&amp;author=AN%20Boscoe&amp;author=C%20Rolland&amp;author=RK.%20Kelley&amp;volume=10&amp;publication_year=2019&amp;pmid=31392056&amp;doi=10.21037/jgo.2019.03.10&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr23-20420986251347376">
<span class="label">23.</span><cite>
U.S. Food and Drug Administration. TIBSOVO® (ivosidenib tablets), for oral use. Initial U.S. approval. Silver Spring, MD: U.S. Food and Drug Administration, 2018. 
</cite> [<a href="https://scholar.google.com/scholar_lookup?U.S.%20Food%20and%20Drug%20Administration.%20TIBSOVO%C2%AE%20(ivosidenib%20tablets),%20for%20oral%20use.%20Initial%20U.S.%20approval.%20Silver%20Spring,%20MD:%20U.S.%20Food%20and%20Drug%20Administration,%202018." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr24-20420986251347376">
<span class="label">24.</span><cite>
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ
2021; 372: n71.</cite> [<a href="https://doi.org/10.1136/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8005924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33782057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20PRISMA%202020%20statement:%20an%20updated%20guideline%20for%20reporting%20systematic%20reviews&amp;author=MJ%20Page&amp;author=JE%20McKenzie&amp;author=PM%20Bossuyt&amp;volume=372&amp;publication_year=2021&amp;pmid=33782057&amp;doi=10.1136/bmj.n71&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr25-20420986251347376">
<span class="label">25.</span><cite>
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ
2019; 366: l4898.</cite> [<a href="https://doi.org/10.1136/bmj.l4898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31462531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=RoB%202:%20a%20revised%20tool%20for%20assessing%20risk%20of%20bias%20in%20randomised%20trials&amp;author=JAC%20Sterne&amp;author=J%20Savovi%C4%87&amp;author=MJ%20Page&amp;volume=366&amp;publication_year=2019&amp;pmid=31462531&amp;doi=10.1136/bmj.l4898&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr26-20420986251347376">
<span class="label">26.</span><cite>
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ
2016; 355: i4919.</cite> [<a href="https://doi.org/10.1136/bmj.i4919" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5062054/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27733354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=ROBINS-I:%20a%20tool%20for%20assessing%20risk%20of%20bias%20in%20non-randomised%20studies%20of%20interventions&amp;author=JA%20Sterne&amp;author=MA%20Hern%C3%A1n&amp;author=BC%20Reeves&amp;volume=355&amp;publication_year=2016&amp;pmid=27733354&amp;doi=10.1136/bmj.i4919&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr27-20420986251347376">
<span class="label">27.</span><cite>
Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol
2020; 21: 671–684.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(20)30109-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8461541/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32203698/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Pemigatinib%20for%20previously%20treated,%20locally%20advanced%20or%20metastatic%20cholangiocarcinoma:%20a%20multicentre,%20open-label,%20phase%202%20study&amp;author=GK%20Abou-Alfa&amp;author=V%20Sahai&amp;author=A%20Hollebecque&amp;volume=21&amp;publication_year=2020&amp;pages=671-684&amp;pmid=32203698&amp;doi=10.1016/S1470-2045(20)30109-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr28-20420986251347376">
<span class="label">28.</span><cite>
Shi G, Huang X, Wen T, et al. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying <em>FGFR2</em> fusions or rearrangements: a phase II study. Cancer Med
2023; 12: 4137–4146.
</cite> [<a href="https://doi.org/10.1002/cam4.5273" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9972033/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36127767/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med&amp;title=Pemigatinib%20in%20previously%20treated%20Chinese%20patients%20with%20locally%20advanced%20or%20metastatic%20cholangiocarcinoma%20carrying%20FGFR2%20fusions%20or%20rearrangements:%20a%20phase%20II%20study&amp;author=G%20Shi&amp;author=X%20Huang&amp;author=T%20Wen&amp;volume=12&amp;publication_year=2023&amp;pages=4137-4146&amp;pmid=36127767&amp;doi=10.1002/cam4.5273&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr29-20420986251347376">
<span class="label">29.</span><cite>
Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for <em>FGFR2</em>-rearranged intrahepatic cholangiocarcinoma. N Engl J Med
2023; 388: 228–239.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2206834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36652354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Futibatinib%20for%20FGFR2-rearranged%20intrahepatic%20cholangiocarcinoma&amp;author=L%20Goyal&amp;author=F%20Meric-Bernstam&amp;author=A%20Hollebecque&amp;volume=388&amp;publication_year=2023&amp;pages=228-239&amp;pmid=36652354&amp;doi=10.1056/NEJMoa2206834&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr30-20420986251347376">
<span class="label">30.</span><cite>
Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with <em>IDH1</em> mutation: the phase 3 randomized clinical ClarIDHy Trial. JAMA Oncol
2021; 7: 1669.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2021.3836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8461552/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34554208/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Final%20overall%20survival%20efficacy%20results%20of%20ivosidenib%20for%20patients%20with%20advanced%20cholangiocarcinoma%20with%20IDH1%20mutation:%20the%20phase%203%20randomized%20clinical%20ClarIDHy%20Trial&amp;author=AX%20Zhu&amp;author=T%20Macarulla&amp;author=MM%20Javle&amp;volume=7&amp;publication_year=2021&amp;pmid=34554208&amp;doi=10.1001/jamaoncol.2021.3836&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr31-20420986251347376">
<span class="label">31.</span><cite>
Common Terminology Criteria for Adverse Events (CTCAE)-Version 4.03 [Internet], <a href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</a> (2010, accessed 24 July 2023).</cite>
</li>
<li id="bibr32-20420986251347376">
<span class="label">32.</span><cite>
Common Terminology Criteria for Adverse Events (CTCAE)-Version 5.0 [Internet], <a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf</a> (2017, accessed 24 July 2023).</cite>
</li>
<li id="bibr33-20420986251347376">
<span class="label">33.</span><cite>
Ilyas SI, Gores GJ.
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology
2013; 145: 1215–1229.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2013.10.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3862291/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24140396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Pathogenesis,%20diagnosis,%20and%20management%20of%20cholangiocarcinoma&amp;author=SI%20Ilyas&amp;author=GJ.%20Gores&amp;volume=145&amp;publication_year=2013&amp;pages=1215-1229&amp;pmid=24140396&amp;doi=10.1053/j.gastro.2013.10.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr34-20420986251347376">
<span class="label">34.</span><cite>
Blechacz B.
Cholangiocarcinoma: current knowledge and new developments. Gut Liver
2017; 11: 13–26.
</cite> [<a href="https://doi.org/10.5009/gnl15568" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5221857/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27928095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut%20Liver&amp;title=Cholangiocarcinoma:%20current%20knowledge%20and%20new%20developments&amp;author=B.%20Blechacz&amp;volume=11&amp;publication_year=2017&amp;pages=13-26&amp;pmid=27928095&amp;doi=10.5009/gnl15568&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr35-20420986251347376">
<span class="label">35.</span><cite>
Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology
2023; 77: 659.
</cite> [<a href="https://doi.org/10.1002/hep.32771" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36083140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=AASLD%20practice%20guidance%20on%20primary%20sclerosing%20cholangitis%20and%20cholangiocarcinoma&amp;author=CL%20Bowlus&amp;author=L%20Arriv%C3%A9&amp;author=A%20Bergquist&amp;volume=77&amp;publication_year=2023&amp;pages=659&amp;pmid=36083140&amp;doi=10.1002/hep.32771&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr36-20420986251347376">
<span class="label">36.</span><cite>
Fallowfield LJ, Fleissig A.
The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol
2011; 9: 41–47.
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2011.156" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22009075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=The%20value%20of%20progression-free%20survival%20to%20patients%20with%20advanced-stage%20cancer&amp;author=LJ%20Fallowfield&amp;author=A.%20Fleissig&amp;volume=9&amp;publication_year=2011&amp;pages=41-47&amp;pmid=22009075&amp;doi=10.1038/nrclinonc.2011.156&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr37-20420986251347376">
<span class="label">37.</span><cite>
Greer JA, Pirl WF, Jackson VA, et al. Perceptions of health status and survival in patients with metastatic lung cancer. J Pain Symptom Manage
2014; 48: 548–557.
</cite> [<a href="https://doi.org/10.1016/j.jpainsymman.2013.10.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24680623/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pain%20Symptom%20Manage&amp;title=Perceptions%20of%20health%20status%20and%20survival%20in%20patients%20with%20metastatic%20lung%20cancer&amp;author=JA%20Greer&amp;author=WF%20Pirl&amp;author=VA%20Jackson&amp;volume=48&amp;publication_year=2014&amp;pages=548-557&amp;pmid=24680623&amp;doi=10.1016/j.jpainsymman.2013.10.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>sj-docx-1-taw-10.1177_20420986251347376 – Supplemental material for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365427/bin/sj-docx-1-taw-10.1177_20420986251347376.docx" data-ga-action="click_feat_suppl" class="usa-link">sj-docx-1-taw-10.1177_20420986251347376.docx</a><sup> (31KB, docx) </sup>
</div></div>
<p>Supplemental material, sj-docx-1-taw-10.1177_20420986251347376 for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review by Giulia Matranga, Anna Carollo, Miriam Alaimo, Sofia Cutaia, Sergio Rizzo and Alessio Provenzani in Therapeutic Advances in Drug Safety</p></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>sj-docx-2-taw-10.1177_20420986251347376 – Supplemental material for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365427/bin/sj-docx-2-taw-10.1177_20420986251347376.docx" data-ga-action="click_feat_suppl" class="usa-link">sj-docx-2-taw-10.1177_20420986251347376.docx</a><sup> (97.5KB, docx) </sup>
</div></div>
<p>Supplemental material, sj-docx-2-taw-10.1177_20420986251347376 for Safety profiles of the new target therapies—pemigatinib, futibatinib, and ivosidenib—for the treatment of cholangiocarcinoma: a systematic review by Giulia Matranga, Anna Carollo, Miriam Alaimo, Sofia Cutaia, Sergio Rizzo and Alessio Provenzani in Therapeutic Advances in Drug Safety</p></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Therapeutic Advances in Drug Safety are provided here courtesy of <strong>SAGE Publications</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1177/20420986251347376"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/10.1177_20420986251347376.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (985.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365427/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365427/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365427%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365427/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365427/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365427/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40842734/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365427/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40842734/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365427/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365427/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="XpOwY2BWmMenyCWhXmcvuPC8GPtyk2bO7uHull7wLtLjSH0kcsrrNPTqjFUT9hlp">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
